This is a Phase I, first in human, open-label dose-escalation study of AC682, an orally available estrogen receptor degrader, given as a single agent.
This clinical trial is evaluating a drug called AC682 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to:~Identify the recommended dose of AC682 that can be given safely to participants~To evaluate the side effects of AC682~To evaluate pharmacokinetics of AC682~To evaluate the effectiveness of AC682